07/24/2025
🎯 Targeted cancer therapies, developed based on genetic (DNA) changes, have improved patient outcomes — but cancer cells often develop resistance.
🧬 Now, next-generation cancer treatment uses proteomics analysis to identify proteins driving tumor growth, and to help explain why targeted therapies often stop working.
At Inova Schar Cancer Institute, we're the first health system in the U.S. using real-time proteomics in our weekly molecular tumor board, led by Dr. Tim Cannon.
🎙️ Learn more: https://bit.ly/44TJpUT via WTOP News 🔗